However, because of the limitations of such real-world studies, these findings should be considered with caution and are likely due to be confounding by indication, in view of the use of different drug classes in the early and late stages of the type 2 diabetes disease trajectory (metformin is used early in the disease trajectory of type 2 diabetes, whereas insulin is typically initiated later). This evidence concerns the gene INS and type 2 diabetes mellitus.